Skip to main content
Clinical Trials/NCT01170598
NCT01170598
Completed
Phase 2

A Pilot Exercise RCT for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy: Pre-randomization Phase

Toronto Rehabilitation Institute1 site in 1 country35 target enrollmentJune 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute Myeloid Leukemia
Sponsor
Toronto Rehabilitation Institute
Enrollment
35
Locations
1
Primary Endpoint
Peak Aerobic Capacity (VO2peak)
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Fatigue, reduced quality of life and declines in physical function are common in patients undergoing chemotherapy for acute myeloid leukaemia (AML). Studies in other cancer patients undergoing treatment have shown that exercise improves these symptoms, but there are limited studies in AML. This study of a hospital-based exercise program will help determine if exercise is both feasible and helpful in improving symptoms among for AML patients undergoing chemotherapy.

Detailed Description

Background: Acute myeloid leukaemia (AML) is a life-threatening haematological malignancy. Initial treatment with induction chemotherapy requires 4-5 weeks of hospitalization, with a risk of physical deconditioning, declines in quality of life (QOL), and significant fatigue. Four pilot exercise studies have demonstrated improved fitness, strength, QOL, and fatigue in patients undergoing induction, but are limited by small sample sizes, recruitment of mostly younger adults, inconsistent endpoints, and design issues. Prior to conducting a large multi-centre randomized controlled trial (RCT), important pilot work first needs to be done to demonstrate feasibility of a randomized trial of an exercise program in AML patients undergoing induction chemotherapy; to ensure safety; and to provide effect estimates of the intervention on fitness and QOL/fatigue endpoints. Objectives: Primary objectives are: (1) to determine feasibility of recruitment and retention of adult AML patients to a randomized trial of supervised exercise and ability of patients to perform an exercise intervention in hospital; (2) to provide estimates of the effect of exercise on fitness parameters. Secondary objectives are: (1) to determine effects of exercise on QOL and fatigue; (2) to understand the impact of exercise on AML treatment tolerability; (3) to examine safety of the exercise intervention. Methods: Thirty-five patients age 18 or older with newly diagnosed or relapsed AML who are undergoing induction chemotherapy will be recruited at Princess Margaret Hospital. Participants will perform 30-45 minutes of supervised aerobic and resistance exercises 4-5 days per week. Primary outcomes are recruitment rate, exercise adherence rate, and impact on fitness measures (peak aerobic capacity (VO2peak), grip strength, leg strength, 6-minute walk test). QOL will be measured with the European Organization for the Research and Treatment of Cancer (EORTC) core 30-item questionnaire (QLQ-C30). Fatigue will be measured using the Functional Assessment of Cancer Therapy fatigue subscale (FACT-Fatigue). Treatment tolerability outcomes include length of stay, intensive care unit admission, and the development of sepsis. Outcomes over time will be assessed using mixed effects regression models. Significance: Exercise is a promising intervention for improving fitness, QOL and treatment tolerability in AML patients undergoing induction chemotherapy. This pilot RCT will establish feasibility and safety, as well as provide efficacy estimates that will be vital to the design and conduct of a definitive multi-centre RCT of exercise in this patient population.

Registry
clinicaltrials.gov
Start Date
June 2010
End Date
March 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shabbir Alibhai

Staff Physician and Scientist

Toronto Rehabilitation Institute

Eligibility Criteria

Inclusion Criteria

  • at least 18 years old
  • newly diagnosed AML, or relapsed AML after having been in complete remission for at least 6 months
  • initiating induction chemotherapy
  • ambulatory without need for human assistance
  • has consented to study
  • is medically cleared for participation by attending physician

Exclusion Criteria

  • has another active malignancy
  • has life expectancy \< 1 month, physician determined
  • has significant comorbidity
  • has uncontrolled pain
  • has haemodynamic instability
  • lacks fluency in reading and writing English and there is no translator available for each visit

Outcomes

Primary Outcomes

Peak Aerobic Capacity (VO2peak)

Time Frame: Baseline, Post-induction (weeks 4-6)

The modified Bruce protocol is a walking-based treadmill test used to assess peak aerobic capacity. As the test progresses the intensity of each 3-minute work load increases. The test concludes when the participant reaches his maximal heart rate or volitional fatigue. The value attained on this test is measured in metabolic equivalents (METS). METS are a measure of exercise intensity and reflect the physical demands of an activity. In this context, a higher value achieved on the treadmill test (in METS) indicates work at a higher intensity and therefore a higher aerobic capacity.

6-minute Walk Test

Time Frame: Baseline, Post-induction (4-6 weeks)

Measure of functional endurance assessed by the walking distance covered in a 6-minute period. Participants walk a pre-established course for a total of 6 minutes. The distance covered in that time is recorded as the 6-minute walk test score.

Timed 10-chair Stands

Time Frame: Baseline, Post-induction (weeks 4-6)

Measure of lower-body strength completed by standing from a seated position 10 times as quickly as possible.

Grip Strength

Time Frame: Baseline, Post-induction (weeks 4-6)

Measure of upper-body strength using a Jamar hand dynamometer. Participants were asked to hold and squeeze (the dynamometer) with maximal force. Three trials were completed with each hand, alternating between the right and left to minimize fatigue. The highest recorded value of the dominant hand was used in the analysis.

Recruitment Rate

Time Frame: Baseline

Ratio of patients who consented to participate out of all eligible patients expressed as a percentage (eligible patients who consented to participation/eligible patients who declined participation).

Retention

Time Frame: Baseline, Post-induction (weeks 4-6)

Percentage of participants who remained in the study (did not withdraw voluntarily).

Program Adherence.

Time Frame: Baseline, Post-induction (weeks 4-6)

Adherence to supervised exercise program assessed as a percentage of exercise sessions completed(number of days of supervised exercise performed/the number of days that patients were approached to participate).

Secondary Outcomes

  • Global Quality of Life(Baseline, Post-induction (weeks 4-6))
  • Fatigue(Baseline, Post-induction (weeks 4-6))
  • Length of Stay(Post-induction (weeks 4-6))
  • Intensive Care Unit (ICU) Admission(Post-induction (weeks 4-6))
  • Development of Sepsis(Post-induction (weeks 4-6))

Study Sites (1)

Loading locations...

Similar Trials